HDAC6 and the intersection between the UPS, autophagy, and neurodegeneration
HDAC6 与 UPS、自噬和神经退行性疾病之间的交叉点
基本信息
- 批准号:8127737
- 负责人:
- 金额:$ 32.04万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-09-15 至 2013-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAndrogen ReceptorAutophagocytosisBindingBiochemicalBiological ModelsBrainBrain StemCAG repeatCell Culture TechniquesCell LineCellsDeacetylaseDefectDiseaseDrosophila genusExonsGenesGeneticGenetic ScreeningGenomicsHealthHeat shock proteinsHereditary DiseaseImpairmentKnock-outKnockout MiceMammalsMapsMicrotubulesModelingMolecularMotor NeuronsMusMutationNerve DegenerationNeurodegenerative DisordersNeuronsPathologyPolyubiquitinProteinsRNA InterferenceReceptor GeneRoleSpinal CordSpinobulbar Muscular AtrophySystemTestingTherapeuticTherapeutic InterventionToxic effectTransgenic OrganismsUbiquitincandidate validationflyhistone deacetylase 6in vivoinsightmouse modelmulticatalytic endopeptidase complexneurotoxicpolyglutamineprotein aggregateprotein misfoldingresponsestress proteintherapeutic developmenttrafficking
项目摘要
DESCRIPTION (provided by applicant): The long-term objective of this project is to characterize the molecular machinery responsible for eliminating misfolded, neurotoxic proteins so that they may be exploited for therapeutic intervention for neurodegenerative diseases such as spinobulbar muscular atrophy (SBMA). SBMA is a hereditary disease characterized by progressive loss of motor neurons in the brainstem and spinal cord. SBMA is caused by trinucleotide (CAG) repeat expansion in the first exon of the androgen receptor gene leading to polyglutamine expansion in AR protein. Like other polyglutamine diseases, SBMA is characterized by accumulation of misfolded protein aggregates in degenerating neurons. Histone deacetylase 6 (HDAC6) is a microtubule-associated deacetylase with intrinsic polyubiquitin-binding activity. We recently determined that over-expression of HDAC6 rescues degeneration in SBMA flies, flies with proteasome mutations, and other fly models of neurodegenerative disease. HDAC6 rescues degeneration by facilitating the degradation of aberrant, ubiquitinated protein by the autophagy-lysosomal system. In this application, we will (1) test specific hypotheses regarding the molecular mechanism whereby HDAC6 facilitates autophagic degradation of aberrant protein, (2) determine the therapeutic potential of HDAC6 in mammals, and (3) use the power of fly genetics to gain unanticipated insights into the role of HDAC6 in cellular management of misfolded protein stress. PUBLIC HEALTH RELEVANCE: Histone deacetylase 6 contributes to elimination of misfolded proteins from neurons and protects against neurodegeneration. It is not known how HDAC6 functions. This application seeks to understand the mechanism of HDAC6 function so that it may be exploited for therapeutics development.
描述(由申请人提供):本项目的长期目标是表征负责消除错误折叠的神经毒性蛋白质的分子机制,以便将其用于神经退行性疾病(如脊髓延髓肌萎缩症(SBMA))的治疗干预。SBMA是一种遗传性疾病,其特征是脑干和脊髓中运动神经元的进行性丧失。SBMA是由雄激素受体基因第一外显子中的三核苷酸(CAG)重复扩增引起的,导致AR蛋白中的多聚谷氨酰胺扩增。与其他多聚谷氨酰胺疾病一样,SBMA的特征是在退化的神经元中错误折叠的蛋白质聚集体的积累。组蛋白去乙酰化酶6(HDAC 6)是一种微管相关的去乙酰化酶,具有内在的多聚泛素结合活性。我们最近确定HDAC 6的过表达挽救了SBMA果蝇、蛋白酶体突变果蝇和其他神经退行性疾病果蝇模型的变性。HDAC 6通过促进自噬-溶酶体系统降解异常的泛素化蛋白质来挽救变性。在本申请中,我们将(1)测试关于HDAC 6促进异常蛋白自噬降解的分子机制的特定假设,(2)确定HDAC 6在哺乳动物中的治疗潜力,以及(3)使用苍蝇遗传学的力量来获得对HDAC 6在错误折叠蛋白应激的细胞管理中的作用的意外见解。公共卫生相关性:组蛋白去乙酰化酶6有助于消除神经元中错误折叠的蛋白质,并防止神经变性。目前尚不清楚HDAC 6的功能。本申请试图了解HDAC 6功能的机制,以便其可用于治疗开发。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joseph Paul Taylor其他文献
Joseph Paul Taylor的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joseph Paul Taylor', 18)}}的其他基金
Dynamic RNA-protein assemblies and neurological disease
动态RNA-蛋白质组装和神经系统疾病
- 批准号:
10300049 - 财政年份:2016
- 资助金额:
$ 32.04万 - 项目类别:
Dynamic RNA-protein assemblies and neurological disease
动态RNA-蛋白质组装和神经系统疾病
- 批准号:
10063575 - 财政年份:2016
- 资助金额:
$ 32.04万 - 项目类别:
Dynamic RNA-protein assemblies and neurological disease
动态RNA-蛋白质组装和神经系统疾病
- 批准号:
9170202 - 财政年份:2016
- 资助金额:
$ 32.04万 - 项目类别:
Dynamic RNA-protein assemblies and neurological disease
动态RNA-蛋白质组装和神经系统疾病
- 批准号:
10518397 - 财政年份:2016
- 资助金额:
$ 32.04万 - 项目类别:
Clinical Research in ALS & Related Disorders for Therapeutic Development (CReATe) - Project Core #2
ALS 临床研究
- 批准号:
10242883 - 财政年份:2014
- 资助金额:
$ 32.04万 - 项目类别:
Clinical Research in ALS & Related Disorders for Therapeutic Development (CReATe) - Project Core #2
ALS 临床研究
- 批准号:
10473844 - 财政年份:2014
- 资助金额:
$ 32.04万 - 项目类别:
Clinical Research in ALS & Related Disorders for Therapeutic Development (CReATe) - Project Core #2
ALS 临床研究
- 批准号:
10020813 - 财政年份:2014
- 资助金额:
$ 32.04万 - 项目类别:
Clinical Research in ALS & Related Disorders for Therapeutic Development (CReATe) - Project Core #2
ALS 临床研究
- 批准号:
10687077 - 财政年份:2014
- 资助金额:
$ 32.04万 - 项目类别:
HDAC6 and the intersection between the UPS, autophagy, and neurodegeneration
HDAC6 与 UPS、自噬和神经退行性疾病之间的交叉点
- 批准号:
8318723 - 财政年份:2008
- 资助金额:
$ 32.04万 - 项目类别:
HDAC6 and the intersection between the UPS, autophagy, and neurodegeneration
HDAC6 与 UPS、自噬和神经退行性疾病之间的交叉点
- 批准号:
7917239 - 财政年份:2008
- 资助金额:
$ 32.04万 - 项目类别:
相似海外基金
Androgen receptor: A master regulator of lipid metabolism
雄激素受体:脂质代谢的主要调节因子
- 批准号:
DP230103210 - 财政年份:2023
- 资助金额:
$ 32.04万 - 项目类别:
Discovery Projects
Regulation of androgen receptor signaling in prostate cancer by protein arginine methylation
通过蛋白质精氨酸甲基化调节前列腺癌中的雄激素受体信号传导
- 批准号:
10584689 - 财政年份:2023
- 资助金额:
$ 32.04万 - 项目类别:
Structural and functional analysis of a novel class of androgen receptor antagonists
一类新型雄激素受体拮抗剂的结构和功能分析
- 批准号:
10650956 - 财政年份:2023
- 资助金额:
$ 32.04万 - 项目类别:
Role of the Androgen Receptor in Insulin Secretion in the Male
雄激素受体在男性胰岛素分泌中的作用
- 批准号:
10488954 - 财政年份:2023
- 资助金额:
$ 32.04万 - 项目类别:
Targeting tumor cell macrophage lipid interactions to overcome resistance to androgen receptor targeted therapy
靶向肿瘤细胞巨噬细胞脂质相互作用以克服对雄激素受体靶向治疗的耐药性
- 批准号:
10651105 - 财政年份:2023
- 资助金额:
$ 32.04万 - 项目类别:
Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease
ONCT-505(一种雄激素受体拮抗剂和降解剂)的临床前开发,作为肯尼迪病的新潜在治疗方法
- 批准号:
10603636 - 财政年份:2023
- 资助金额:
$ 32.04万 - 项目类别:
Proliferating cell nuclear antigen in regulation of androgen receptor signalings in castration-resistant prostate cancer cells
增殖细胞核抗原对去势抵抗性前列腺癌细胞雄激素受体信号传导的调节
- 批准号:
10544062 - 财政年份:2022
- 资助金额:
$ 32.04万 - 项目类别:
Effects of androgen receptor (AR) signaling on CD4+ T cell metabolism during airway inflammation
气道炎症期间雄激素受体 (AR) 信号对 CD4 T 细胞代谢的影响
- 批准号:
10534943 - 财政年份:2022
- 资助金额:
$ 32.04万 - 项目类别:
TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE
标题:使用雄激素受体抑制剂阿帕鲁胺进行膀胱癌化学预防
- 批准号:
10677989 - 财政年份:2022
- 资助金额:
$ 32.04万 - 项目类别:














{{item.name}}会员




